Janux Therapeutics (JANX) vs Lexicon Pharmaceuticals (LXRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Lexicon Pharmaceuticals (LXRX) has outperformed Janux Therapeutics (JANX) over the past year, gaining 14.2% versus a loss of 65.0%. Over five years, JANX leads with a -42.9% price change compared with -67.7% for LXRX. Lexicon Pharmaceuticals is the larger company by market cap ($681.2 million vs $616.7 million), about 1.1 times the size.
Lexicon Pharmaceuticals converts more of its revenue into profit, with a net margin of -101.1% versus -1136.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | JANX | LXRX |
|---|---|---|
| Share price | $10.08 | $1.53 |
| Market cap | $616.73M | $681.21M |
| 1-day change | -2.04% | -8.38% |
| YTD return | -26.96% | +33.04% |
| 1-year return | -65.00% | +14.18% |
| 5-year return | -42.92% | -67.72% |
| EPS (TTM) | $-1.59 | $-0.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $10.00M | $49.80M |
| Revenue growth (YoY) | -5.55% | +60.24% |
| Net income (latest FY) | $-113.63M | $-50.34M |
| Gross margin | — | 99.45% |
| Operating margin | -1576.67% | -98.21% |
| Net margin | -1136.25% | -101.08% |
| 52-week high | $35.34 | $2.68 |
| 52-week low | $10.05 | $1.10 |
| Distance from 52-week high | -71.48% | -42.91% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +228.77% | +195.42% |
| Average volume | 961.56K | 2.56M |
| Shares outstanding | 61.18M | 445.23M |
| Employees | 114 | 81 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LXRX has outperformed JANX by 79.2 percentage points over the past year.
- Lexicon Pharmaceuticals is more profitable, keeping -101.1 cents of every revenue dollar as net income versus -1136.3 cents for Janux Therapeutics.
- Lexicon Pharmaceuticals grew revenue faster in its latest fiscal year (+60.24% vs -5.55%).
About Janux Therapeutics
JANX stock →Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 114 employees
About Lexicon Pharmaceuticals
LXRX stock →Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 81 employees
JANX vs LXRX FAQ
Which is bigger, Janux Therapeutics or Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals (LXRX) is larger, with a market capitalization of $681.21M compared with $616.73M for Janux Therapeutics (JANX).
Which stock has performed better over the past year, JANX or LXRX?
LXRX returned +14.18% over the past 12 months, compared with -65.00% for JANX (price return, excluding dividends). Past performance does not predict future results.
Are Janux Therapeutics and Lexicon Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.